Page 2,308«..1020..2,3072,3082,3092,310..2,3202,330..»

Amgen Releases A Giant Genetic Portrait Of A Nation — And A Map Of The Future

Posted: Published on March 26th, 2015

Its the most complete genetic map of an entire country yet completed and it could show clues of what medicine could look like in the coming age of big data. Researchers working at DeCode Genetics, a unit of the drug company Amgen, have sequenced the genomes of 2,636 Icelanders and used genealogical records and more spotty genetic data to calculate the likely genetics of 101,584 more. Because DeCode has anonymized access to patient medical records, the company could then look for relationships between the genetic variants and disease and they found a new genetic variant that increases the risk of Alzheimers, as well as confiming suspected variants that raise the risk of diabetes and one that causes atrial fibrillation, a heart condition. The results are published in three scientific papers in the journal Nature. Its certainly an impressive tour de force, says George Yancopoulos, the Chief Scientific Officer of Amgen rival Regeneron. This is certainly establishing a benchmark for all of us and showing the value of this type of analysis, in particular in the Icelandic population. Regeneron is creating its own database of sequencing data with Pennsylvanias Geisinger Health Systems. The United Kingdom has embarked on a 100,000 Genomes … Continue reading

Comments Off on Amgen Releases A Giant Genetic Portrait Of A Nation — And A Map Of The Future

Developing stem cell therapy as an alternative to corneal transplants. – Video

Posted: Published on March 26th, 2015

Developing stem cell therapy as an alternative to corneal transplants. Professor Julie Daniels talks about her tissue engineering research. By: Fight for Sight … Continue reading

Comments Off on Developing stem cell therapy as an alternative to corneal transplants. – Video

No stem cell treatment for public servant's dodgy knee

Posted: Published on March 26th, 2015

A federal public servant has lost a legal bid to have taxpayers pay for experimental stem cell treatment on his dodgy knees. The Administrative Appeals Tribunal has knocked back an appeal by Customs officer Vic Kaplicas to force insurer Comcare to pay $13,400 for the new treatment, instead saying he could have a tried-and-tested double knee replacement. But the 49-year-old border official says he worries he cannot pass his department's fitness tests if he undergoes the knee replacements, which will leave him unable to run. Advertisement The former triathlete, who had to give up his sport because of his bad knees, said he was keen to avoid the "radical but effective" replacements for as long as possible. Mr Kaplicas hurt his left knee working at Sydney's Mascot Airport in 2000, then injured his right knee 10 years later at Kingsford-Smith. He managed the pain in his knees, which have since developed osteoarthritis, for years using over-the-counter painkillers, physio, exercises and injections but Mr Kaplicas' doctors say a more permanent solution is now needed. In June 2012, Sydney knee specialist Sam Sorrenti asked Comcare to pay for bilateral knee stem cell assisted arthroscopic surgery for Mr Kaplicas. The cost of the … Continue reading

Comments Off on No stem cell treatment for public servant's dodgy knee

UCI team gets $5 million to create stem cell treatment for Huntington's disease

Posted: Published on March 26th, 2015

Irvine, Calif., March 26, 2015 -- Leslie Thompson of the Sue & Bill Gross Stem Cell Research Center at UC Irvine has been awarded $5 million by the California Institute for Regenerative Medicine to continue her CIRM-funded effort to develop stem cell treatments for Huntington's disease. The grant supports her next step: identifying and testing stem cell-based treatments for HD, an inherited, incurable and fatal neurodegenerative disorder. In this project, Thompson and her colleagues will establish an HD therapy employing human embryonic stem cells that can be evaluated in clinical trials. Over the past seven years, Thompson, a UCI professor of psychiatry & human behavior and neurobiology & behavior, and her team have used CIRM funding to produce stem cell lines "reprogrammed" from the skin cells of individuals carrying the Huntington's genetic mutation in order to study the disease. In addition, they conducted basic and early-stage transitional studies to develop a stem cell-based technique to treat areas of the brain susceptible to HD. "These stem cells offer a possible long-term treatment approach that could relieve the tremendous suffering experienced by HD patients and their families," said Thompson, who's also affiliated with UCI's Institute for Memory Impairments and Neurological Disorders (UCI … Continue reading

Comments Off on UCI team gets $5 million to create stem cell treatment for Huntington's disease

Profiles in Nanomedicine Research: Wannemuehler – Video

Posted: Published on March 26th, 2015

Profiles in Nanomedicine Research: Wannemuehler By: ISUengineering … Continue reading

Comments Off on Profiles in Nanomedicine Research: Wannemuehler – Video

Researchers Use Nanoparticles to Selectively Target Tumor Cells in Two Cancer Models

Posted: Published on March 26th, 2015

Contact Information Available for logged-in reporters only Newswise Nanoparticles hold great promise for cancer diagnostics and therapies, but only to the extent that they can be selectively guided to tumors and cancer cells. Leading a multidisciplinary group from Dartmouth College, Karl E. Griswold, PhD published, "Antibody-mediated targeting of iron oxide nanoparticles to the Folate receptor alpha increases tumor cell association in vitro and in vivo," in the International Journal of Nanomedicine, which follows closely the publication of "Tumor Cell Targeting by Iron Oxide Nanoparticles is Dominated by Different Factors in Vitro versus in Vivo," published in PLOS ONE. "The ultimate utility of anti-cancer nanoparticle technologies will depend in large part on their capacity to selectively home to cancer cells," explained Griswold. "Achieving optimal targeting of nanoparticles in clinically relevant scenarios remains a key challenge for researchers in this space." The in vivo environment is enormously complex, and there exists an extensive array of variables that determine distribution and cellular targeting of nanoparticles in the body. Homing of nanoparticles to tumors is dependent upon parameters such as nanoparticle size and composition, molecular targeting, surface chemistry, route of administration, cancer cell type, and tumor location. Using carefully designed and rigorously validated functional … Continue reading

Comments Off on Researchers Use Nanoparticles to Selectively Target Tumor Cells in Two Cancer Models

Blood test uses human stem cells to predict severe drug reactions

Posted: Published on March 26th, 2015

Scientists have developed a blood test using human stem cells that predicts whether new drugs will cause severe side effects. The test, which only requires blood from a single donor, could help prevent catastrophic inflammatory reactions known as a cytokine storm in people participating in drug trials. "As biological therapies become more mainstream, its more likely that drugs being tested on humans for the first time will have unexpected and potentially catastrophic effects," says Professor Jane Mitchell from the National Heart and Lung Institute at Imperial College London, who led the study. "Weve used adult stem cell technology to develop a laboratory test that could prevent another disaster like the TGN1412 trial." In 2006 six healthy young men were hospitalized with multiple organ failure after experiencing a cytokine storm as a result of taking part in the first tests in humans of the drug TGN1412. Tests on human cells are essential because biological therapies, or "biologics" (such as the cancer drugs Herceptin and Avastin), use antibodies which are specific to humans. They can cause severe reactions, such as a cytokine storm, that dont occur in animal studies. Cytokine storm reactions are difficult to predict using tests where just one cell … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Blood test uses human stem cells to predict severe drug reactions

No stem cell treatment for public servant's dodgy knee

Posted: Published on March 26th, 2015

A federal public servant has lost a legal bid to have taxpayers pay for experimental stem cell treatment on his dodgy knees. The Administrative Appeals Tribunal has knocked back an appeal by Customs officer Vic Kaplicas to force insurer Comcare to pay $13,400 for the new treatment, instead saying he could have a tried-and-tested double knee replacement. But the 49-year-old border official says he worries he cannot pass his department's fitness tests if he undergoes the knee replacements, which will leave him unable to run. Advertisement The former triathlete, who had to give up his sport because of his bad knees, said he was keen to avoid the "radical but effective" replacements for as long as possible. Mr Kaplicas hurt his left knee working at Sydney's Mascot Airport in 2000, then injured his right knee 10 years later at Kingsford-Smith. He managed the pain in his knees, which have since developed osteoarthritis, for years using over-the-counter painkillers, physio, exercises and injections but Mr Kaplicas' doctors say a more permanent solution is now needed. In June 2012, Sydney knee specialist Sam Sorrenti asked Comcare to pay for bilateral knee stem cell assisted arthroscopic surgery for Mr Kaplicas. The cost of the … Continue reading

Comments Off on No stem cell treatment for public servant's dodgy knee

OvaScience to Host Conference Call and Webcast Presentation with IVF Specialists to Review Early AUGMENT Fertility …

Posted: Published on March 25th, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today a conference call focused on the AUGMENTSM treatment on Friday, March 27, 2015 at 10:00 am ET. The presentation will follow an AUGMENT treatment presentation at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting, which represents the first time detailed clinical experience will be presented. Company management will be joined by two leading in vitro fertilization (IVF) specialists among the first to use the AUGMENT treatment in clinical practice. Robert Casper, M.D., F.R.C.S.(C), Medical Director of TCART Fertility Partners in Toronto, Canada, and Kutluk Oktay, M.D., F.A.C.O.G, of Gen-art IVF in Ankara, Turkey, will present initial AUGMENT experience from their respective clinics, including select patient case studies. The AUGMENT treatment is not available in the United States. A live, listen-only presentation can be accessed via webcast by visiting the Investors section of the Companys website at http://www.ovascience.com. The call can be accessed by dialing (877) 930-8299 (U.S.) or (253) 336-8765 (international) five minutes prior to the start of the call and providing the passcode 14733732. A replay of the webcast will be archived on the Companys … Continue reading

Posted in IVF Treatment | Comments Off on OvaScience to Host Conference Call and Webcast Presentation with IVF Specialists to Review Early AUGMENT Fertility …

ASHG and ESHG issue position statement on non-invasive prenatal screening

Posted: Published on March 25th, 2015

BETHESDA, MD, USA and VIENNA, AUSTRIA - Two of the world's largest professional societies of human geneticists have issued a joint position statement on the promise and challenges of non-invasive prenatal testing (NIPT), a new procedure to test blood drawn from pregnant mothers for Down syndrome and other chromosomal disorders in the fetus. The document addresses the current scope of and likely future improvements in NIPT technology, ways it may best fit with existing prenatal screening tools and protocols, options and priorities in its implementation, and associated social and ethical issues. The statement, drafted by the Social Issues Committee of the American Society of Human Genetics (ASHG) and the Public and Professional Policy Committee of the European Society of Human Genetics (ESHG), was published online March 18 in the European Journal of Human Genetics. Current prenatal screening protocols for common structural abnormalities in the chromosomes vary among countries and medical practices. Generally, though, pregnant women are offered a combined first-trimester screening (cFTS), a risk assessment test based on blood and ultrasound markers. Women who receive abnormal cFTS results undergo a second step of testing to confirm or deny whether the fetus has an abnormality such as Down syndrome. This second … Continue reading

Posted in Human Genetics | Comments Off on ASHG and ESHG issue position statement on non-invasive prenatal screening

Page 2,308«..1020..2,3072,3082,3092,310..2,3202,330..»